IL302176A - Suitable multivalent carriers and vaccine compositions - Google Patents

Suitable multivalent carriers and vaccine compositions

Info

Publication number
IL302176A
IL302176A IL302176A IL30217623A IL302176A IL 302176 A IL302176 A IL 302176A IL 302176 A IL302176 A IL 302176A IL 30217623 A IL30217623 A IL 30217623A IL 302176 A IL302176 A IL 302176A
Authority
IL
Israel
Prior art keywords
coronavirus
vaccine composition
protein
antigens
antigen
Prior art date
Application number
IL302176A
Other languages
English (en)
Hebrew (he)
Inventor
Alexander A Cohen
Pamela J Bjorkman
Original Assignee
California Inst Of Techn
Alexander A Cohen
Pamela J Bjorkman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn, Alexander A Cohen, Pamela J Bjorkman filed Critical California Inst Of Techn
Publication of IL302176A publication Critical patent/IL302176A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL302176A 2020-11-11 2021-11-10 Suitable multivalent carriers and vaccine compositions IL302176A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112495P 2020-11-11 2020-11-11
PCT/US2021/058856 WO2022103891A1 (en) 2020-11-11 2021-11-10 Multivalent carriers and related vaccine compositions

Publications (1)

Publication Number Publication Date
IL302176A true IL302176A (en) 2023-06-01

Family

ID=81602587

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302176A IL302176A (en) 2020-11-11 2021-11-10 Suitable multivalent carriers and vaccine compositions

Country Status (9)

Country Link
US (2) US12440553B2 (cg-RX-API-DMAC10.html)
EP (1) EP4243867A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023549017A (cg-RX-API-DMAC10.html)
KR (1) KR20230107304A (cg-RX-API-DMAC10.html)
CN (1) CN117098553A (cg-RX-API-DMAC10.html)
AU (1) AU2021378792A1 (cg-RX-API-DMAC10.html)
CA (1) CA3193843A1 (cg-RX-API-DMAC10.html)
IL (1) IL302176A (cg-RX-API-DMAC10.html)
WO (1) WO2022103891A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4182687A4 (en) * 2020-07-20 2024-09-11 Bio-Rad Laboratories, Inc. IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR
WO2023102476A1 (en) 2021-12-02 2023-06-08 California Institute Of Technology Antibodies for coronaviruses and uses thereof
WO2024006532A2 (en) * 2022-06-30 2024-01-04 La Jolla Institute For Immunology Kari nanoparticle
CN117582492A (zh) * 2022-08-12 2024-02-23 上海市公共卫生临床中心 重组多价疫苗
JP2025529906A (ja) * 2022-08-22 2025-09-09 ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド コロナウイルスに対するワクチン
CN115894716B (zh) * 2022-11-23 2024-02-09 华中农业大学 一种重组融合蛋白纳米颗粒及其制备方法
CN117362447B (zh) * 2023-08-25 2024-04-09 广东省农业科学院农业生物基因研究中心 一种基于蛋白质偶联聚合体的生物发光酶联免疫分析方法
WO2025255622A1 (en) * 2024-06-13 2025-12-18 University Of Technology Sydney Method of vaccine prototyping

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
CA2608515A1 (en) * 2005-06-01 2007-05-10 Dow Global Technolgies Inc. Production of multivalent virus like particles
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
US20190105282A1 (en) * 2016-03-23 2019-04-11 Che-Ming Jack Hu Thin-shell polymeric nanoparticles and uses thereof
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine

Also Published As

Publication number Publication date
EP4243867A1 (en) 2023-09-20
AU2021378792A9 (en) 2023-07-13
US20260077034A1 (en) 2026-03-19
JP2023549017A (ja) 2023-11-22
CA3193843A1 (en) 2022-05-19
KR20230107304A (ko) 2023-07-14
CN117098553A (zh) 2023-11-21
US20220168414A1 (en) 2022-06-02
US12440553B2 (en) 2025-10-14
WO2022103891A1 (en) 2022-05-19
AU2021378792A1 (en) 2023-05-04
EP4243867A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US12440553B2 (en) Multivalent carriers and related vaccine compositions
Yan et al. Structural biology of SARS-CoV-2: open the door for novel therapies
Guo et al. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Zhu et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine
JP5215865B2 (ja) ノロウイルス抗原およびサポウイルス抗原
WO2022088953A1 (zh) SARS-CoV-2 RBD共轭纳米颗粒疫苗
TWI886659B (zh) 痘病毒多抗原嵌合疫苗及其用途
CN106794239B (zh) 对抗肠病毒感染的基于腺病毒载体的疫苗
JP5894528B2 (ja) 抗原−ノロウイルスpドメインモノマーおよびダイマー、抗原−ノロウイルスp粒子分子、ならびにそれらの製造および使用法
CN101022827A (zh) 用于治疗冠状病毒感染的疫苗组合物
JP7382634B2 (ja) 交差免疫抗原ワクチン及びその調製方法
Narayanan et al. Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy
CN114835819A (zh) SARS-CoV-2 S1偶联纳米颗粒及其应用
US20230321219A1 (en) SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS [SARS-CoV-2]-VIRUS-LIKE PARTICLE [VLP] VACCINE: COMPOSITIONS, DELIVERY STRATEGIES, METHODS AND USES
US20250011396A1 (en) Multivalent carriers and related vaccine compositions
EP4347622A1 (en) Reconstitution and uses of flavivirus epitopes
JPH03164181A (ja) 豚コレラウイルスワクチン
KR102873285B1 (ko) 스캐폴드 기반의 다중항원을 포함하는 코로나바이러스 감염병 예방 또는 치료용 항원 조성물
JP2018531256A (ja) デングウイルスワクチンおよび診断のための方法および組成物
JP2018531256A6 (ja) デングウイルスワクチンおよび診断のための方法および組成物
KR102959050B1 (ko) 변형된 사스-코로나바이러스-2 ORF3a 폴리펩타이드 및 이의 용도
WO2025081050A1 (en) Coronavirus stem helix and fusion peptide nanoparticle vaccines
US20240092840A1 (en) Vaccine formulation comprising recombinant overlapping peptides and native proteins
Geng Receptor recognition of SARS-CoV-2 and vaccine design
WO2025260633A1 (zh) Rsv和hmpv融合f蛋白及其用途